ASX Announcement – 27 October 2026 LIVER FIBROSIS RESULTS OPEN UP GLP-1 BIOMARKER OPPORTUNITY Highlights • FibrosisAssessment aims to measure fibrosis in the liver using MRI sequences without expensive hardware or invasive contrast injections • Fibrosis in the liver is a key biomarker...
Liver Fibrosis Device - EPoC Study Results
Filed with ASX ·
6ix is reading this filing.
Earlier from Resonance Health
- Trading Halt
- Global Strategic Alliance & MSA with Image Analysis Group
- FY26 Full Year Results & Investor Webinar
- Liver Fibrosis Device Progress & FY26 Portfolio Webinar
- Profit Guidance Upgrade
Later from Resonance Health
- $6.0 Million Placement Oversubscribed
- Investor Presentation Liver Fibrosis Device & Capital Raise
- Liver Fibrosis Device Webinar Presentation
